Hop bitter acids inhibit tumorigenicity of hepatocellular carcinoma cells in vitro

Saugspier,Michael; Dorn,Christoph; Czech,Barbara; Gehrig,Manfred; Heilmann,Jörg; Hellerbrand,Claus

doi:10.3892/or.2012.1925

Hop bitter acids inhibit tumorigenicity of hepatocellular carcinoma cells in vitro

Authors:
- Michael Saugspier
- Christoph Dorn
- Barbara Czech
- Manfred Gehrig
- Jörg Heilmann
- Claus Hellerbrand
View Affiliations

Affiliations: Department of Internal Medicine I, University Hospital Regensburg, Regensburg, Germany, Nateco2 GmbH & Co. KG, Wolnzach, Germany, Department of Pharmaceutical Biology, Institute of Pharmacy, University of Regensburg, Regensburg, Germany
Published online on: July 20, 2012 https://doi.org/10.3892/or.2012.1925
Pages: 1423-1428

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bitter acids (BAs) from the hop plant Humulus lupulus L. exhibit multiple beneficial biological properties with promising effects in cancer therapy and prevention, but information regarding the effects on hepatocellular carcinoma (HCC) is missing. Here, we used two different hop bitter acid extracts enriched for either α-acids or β-acids to obtain insight into whether biological activity varies between these two groups of BAs. At a concentration of 25 µg/ml, only the β-acid rich started to induce aspartate transaminase (AST) release, and a significant increase was detected with 50 µg/ml of both extracts. Already at lower concentrations both extracts led to a dose-dependent inhibition of proliferation, and migration was suppressed at a concentration as low as 5 µg/ml in HCC cells. The focus on different signaling pathways revealed an inhibition of ERK1/2 phosphorylation, downregulation of AP-1 activity and an alleviation of nuclear factor κB (NFκB) activity in HepG2 cells incubated with 5 µg/ml of both extracts, whereby the β-acid rich extract showed more pronounced effects. In conclusion, we identified ERK1/2, AP-1 and NFκB, which are important factors in tumor development and progression, as targets of hop BAs. Thus, these data suggest the potential use of BAs as functional nutrients for both prevention and treatment of HCC.

View Figures

View References

1	Van Cleemput, Cattoor K, De Bosscher K, Haegeman G, De Keukeleire D and Heyerick A: Hop (Humulus lupulus)-derived bitter acids as multipotent bioactive compounds. J Nat Prod. 72:1220–1230. 2009.
2	Chen WJ and Lin JK: Mechanisms of cancer chemoprevention by hop bitter acids (beer aroma) through induction of apoptosis mediated by Fas and caspase cascades. J Agric Food Chem. 52:55–64. 2004. View Article : Google Scholar : PubMed/NCBI
3	Lamy V, Roussi S, Chaabi M, Gosse F, Schall N, Lobstein A and Raul F: Chemopreventive effects of lupulone, a hop {beta}-acid, on human colon cancer-derived metastatic SW620 cells and in a rat model of colon carcinogenesis. Carcinogenesis. 28:1575–1581. 2007.
4	Lamy V, Roussi S, Chaabi M, Gosse F, Lobstein A and Raul F: Lupulone, a hop bitter acid, activates different death pathways involving apoptotic TRAIL-receptors, in human colon tumor cells and in their derived metastatic cells. Apoptosis. 13:1232–1242. 2008. View Article : Google Scholar
5	Tobe H, Kubota M, Yamaguchi M, Kocha T and Aoyagi T: Apoptosis to HL-60 by humulone. Biosci Biotechnol Biochem. 61:1027–1029. 1997. View Article : Google Scholar : PubMed/NCBI
6	Yasukawa K, Takeuchi M and Takido M: Humulon, a bitter in the hop, inhibits tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin. Oncology. 52:156–158. 1995. View Article : Google Scholar : PubMed/NCBI
7	Kirchner G, Kirovski G, Hebestreit A, Scholmerich J, Schlitt HJ, Stoeltzing O and Hellerbrand C: Epidemiology and survival of patients with hepatocellular carcinoma in Southern Germany. Int J Clin Exp Med. 3:169–179. 2010.PubMed/NCBI
8	Bruix J, Boix L, Sala M and Llovet JM: Focus on hepatocellular carcinoma. Cancer Cell. 5:215–219. 2004. View Article : Google Scholar
9	Farazi PA and DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 6:674–687. 2006. View Article : Google Scholar : PubMed/NCBI
10	Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 94:153–156. 2001. View Article : Google Scholar : PubMed/NCBI
11	Freise C, Ruehl M, Erben U, et al: A hepatoprotective Lindera obtusiloba extract suppresses growth and attenuates insulin like growth factor-1 receptor signaling and NF-kappaB activity in human liver cancer cell lines. BMC Complement Altern Med. 11:392011.PubMed/NCBI
12	Amann T, Bataille F, Spruss T, et al: Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci. 100:646–653. 2009. View Article : Google Scholar : PubMed/NCBI
13	Saugspier M, Dorn C, Thasler WE, Gehrig M, Heilmann J and Hellerbrand C: Hop bitter acids exhibit anti-fibrogenic effects on hepatic stellate cells in vitro. Exp Mol Pathol. 92:222–228. 2012. View Article : Google Scholar : PubMed/NCBI
14	Dorn C, Weiss TS, Heilmann J and Hellerbrand C: Xanthohumol, a prenylated chalcone derived from hops, inhibits proliferation, migration and interleukin-8 expression of hepatocellular carcinoma cells. Int J Oncol. 36:435–441. 2010.PubMed/NCBI
15	Ito Y, Sasaki Y, Horimoto M, et al: Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology. 27:951–958. 1998. View Article : Google Scholar : PubMed/NCBI
16	Schmitz KJ, Wohlschlaeger J, Lang H, et al: Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol. 48:83–90. 2008. View Article : Google Scholar : PubMed/NCBI
17	Tsuboi Y, Ichida T, Sugitani S, et al: Overexpression of extracellular signal-regulated protein kinase and its correlation with proliferation in human hepatocellular carcinoma. Liver Int. 24:432–436. 2004. View Article : Google Scholar : PubMed/NCBI
18	Nakano H, Shindo M, Sakon S, Nishinaka S, Mihara M, Yagita H and Okumura K: Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc Natl Acad Sci USA. 95:3537–3542. 1998. View Article : Google Scholar
19	Zhao Q and Lee FS: Mitogen-activated protein kinase/ERK kinase kinases 2 and 3 activate nuclear factor-kappaB through IkappaB kinase-alpha and IkappaB kinase-beta. J Biol Chem. 274:8355–8358. 1999. View Article : Google Scholar : PubMed/NCBI
20	Arsura M and Cavin LG: Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett. 229:157–169. 2005. View Article : Google Scholar : PubMed/NCBI
21	Pikarsky E, Porat RM, Stein I, et al: NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 431:461–466. 2004. View Article : Google Scholar : PubMed/NCBI
22	Cattoor K, Bracke M, Deforce D, De KD and Heyerick A: Transport of hop bitter acids across intestinal Caco-2 cell monolayers. J Agric Food Chem. 58:4132–4140. 2010. View Article : Google Scholar : PubMed/NCBI
23	Foster BC, Kearns N, Arnason JT, Saleem A, Ogrodowczyk C and Desjardins S: Comparative study of hop-containing products on human cytochrome p450-mediated metabolism. J Agric Food Chem. 57:5100–5105. 2009. View Article : Google Scholar : PubMed/NCBI
24	Desai A, Konda VR, Darland G, et al: META060 inhibits multiple kinases in the NF-kappaB pathway and suppresses LPS-mediated inflammation in vitro and ex vivo. Inflamm Res. 58:229–234. 2009. View Article : Google Scholar : PubMed/NCBI
25	Farber SM, Masten JM, Anderson HH, Gentry RW and Chin YC: Tolerance and effects of lupulon in man. Dis Chest. 18:10–15. 1950. View Article : Google Scholar : PubMed/NCBI